Article Text

Download PDFPDF
Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

What are the effects of olanzapine, risperidone, quetiapine, perphenazine and ziprasidone on psychosocial functioning in people with schizophrenia?

Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE Study. Am J Psychiatry 2007;164:428–36.


Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:

Not clear.

Embedded ImageBlinding:

Double blind.

Embedded ImageFollow-up period:

Eighteen months (treatment period only).

Embedded ImageSetting:

Fifty seven clinical sites in the USA; January 2001 to December 2004.

Embedded ImagePatients:

1493 adults with DSM-IV schizophrenia were randomised in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study. This publication reports on the 455 participants who were assessed for the primary outcome measure at baseline and 12 months. Main exclusions: history of antipsychotic resistance, only one previous schizophrenic episode, schizoaffective disorder, mental retardation, other cognitive disorders, pregnant or breast feeding, or serious medical comorbidity.

Embedded ImageIntervention:

Olanzapine (7.5–30 mg), quetiapine (200–800 mg), risperidone (1.5–6 mg), …

View Full Text


  • Sources of funding: National Institute of Mental Health, USA; The Foundation of Hope, Raleigh, NC. Study medications were provided by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Pharmaceuticals Inc, Janssen Pharmaceutica Products LP, Otsuka Pharmaceuticals Co Ltd, Pfizer Inc, and Zenith Goldline Pharmaceuticals Inc.


  • Competing interests: None declared.